Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Spinal Muscular Atrophy (SMA) – Drugs In Development, 2024 report and make more profitable business decisions.
Spinal muscular atrophy (SMA) is a genetic disease that attacks nerve cells, called motor neurons, in the spinal cord. These critically important cells are responsible for supplying electrical and chemical messages to muscle cells. Without the proper input from the motor neurons, muscle cells cannot function properly. The muscle cells will, therefore, become much smaller (atrophy) and will produce symptoms of muscle weakness. This can affect walking, crawling, breathing, swallowing, and head and neck control.
The Spinal Muscular Atrophy (SMA) drugs in development market research report provide comprehensive information on the therapeutics under development for Spinal Muscular Atrophy (SMA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Muscular Atrophy (SMA) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Spinal Muscular Atrophy (SMA) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 52 molecules, with 40 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Spinal Muscular Atrophy (SMA) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Spinal Muscular Atrophy (SMA) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Spinal Muscular Atrophy (SMA) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alcyone Therapeutics IncAlphaCognition Inc
Anima Biotech Inc
Apteeus SAS
Avenue Therapeutics Inc
Beijing GeneCradle Technology Co Ltd
Biocad
Biogen Inc
Biohaven Ltd
Brigham and Women's Hospital
California Institute for Biomedical Research
CANbridge Life Sciences Ltd
ECM Therapeutics Inc
Epirium Bio Inc
Exegenesis Bio Inc
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genethon SA
Hangzhou Jiayin Biotechnology Co Ltd
Harvard University
Intas Pharmaceuticals Ltd
Iowa State University
Karolinska Institute
Myocea Inc
National Institute of Neurological Disorders and Stroke
Nido Biosciences Inc
NMD Pharma AS
Novartis Gene Therapies
Oncternal Therapeutics
PeptiDream Inc
Praxis Biotech LLC
PTC Therapeutics Inc
Ractigen Therapeutics Inc
Reborna Biosciences Inc
Salk Institute for Biological Studies
Scholar Rock Inc
Shenzhen Ruijian Life Science Research Institute Co Ltd
Shift Pharmaceuticals
Skyline Therapeutics (Shanghai) Co Ltd
Suzhou GenAssist Therapeutics Co Ltd
University of Edinburgh
University of Sheffield
University of Western Australia
VeraMorph LLC
Voyager Therapeutics Inc
Vybion Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Spinal Muscular Atrophy (SMA) reports